CVS Pays $315 Million to Settle DOJ Opioid Prescription Case

CVS Pharmacy Inc. and various subsidiaries have agreed to pay $315 million to resolve a Justice Department case alleging it unlawfully dispensed medically unnecessary prescriptions of highly addictive opioids, officials said Tuesday.

The settlement resolves a lawsuit brought in 2024 that accused the healthcare giant of prescribing massive amounts of opioids and other controlled substances "to fuel its own profits at the expense of public health and safety."

Allegations and Settlement Terms

The lawsuit, filed under President Joe Biden’s administration, accused CVS of violating the Controlled Substances Act by filling illegitimate prescriptions for high doses of potent opioids that "fed dependence and addiction." The Justice Department alleged the company dispensed large quantities of opioids based on prescriptions from known "pill mills," or providers that hand out prescriptions for drugs without a legitimate medical purpose.

According to the lawsuit, poor staffing levels coupled with performance metrics and incentive compensation policies implemented by the company led to pharmacists racing to fill prescriptions without confirming they were legitimate. The prescriptions were often billed to and reimbursed by Medicaid and other federal healthcare programs.

Assistant Attorney General Brett Shumate, who leads the Justice Department’s Civil Division, said in a statement that under the settlement, CVS must also "implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate."

Associate Attorney General Stanley Woodward said in an emailed statement, "Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances."

CVS Response

CVS said in a statement that its pharmacists were trained "in the safe and appropriate use of all medications" and that it had implemented "best-in-class" programs to help them "make the best decisions on behalf of patients."

The company said it strongly disagreed with the claims made in the lawsuit and that the settlement admits no wrongdoing. In 2024, the company stated that pharmacists were being held to "vague, undefined, and ever-changing standards of practice" when it comes to filling prescription opioids.

Context of Opioid Settlements

This settlement is the latest effort by the federal government to hold accountable companies that officials have alleged helped fuel the U.S. addiction and overdose crisis. Over the last decade, drugmakers, wholesalers, pharmacies and other companies have agreed to settlements with governments in the U.S. totaling over $50 billion.

Most of the money is intended to go to address the crisis, which has been linked to more than 100,000 deaths in the U.S. some years, though the numbers have fallen sharply recently. Most of the settlements — and dollars — have been with state and local governments, but the U.S. has reached several deals, including in the last two years with the pharmacies Walgreens and Walmart.

Why it matters

The $315 million payment highlights ongoing federal scrutiny of pharmacy practices regarding controlled substances. While CVS denies wrongdoing, the requirement to implement additional safeguards signals a continued regulatory focus on preventing the dispensing of medically unnecessary opioids. This case adds to a broader pattern of multi-billion dollar settlements aimed at addressing the public health impact of the opioid epidemic.

---

Sources

• thestar.com: CVS agrees to pay $315 million to settle Justice Department case over opioid prescriptions
• winnipegfreepress.com: CVS agrees to pay $315 million to settle Justice Department case over opioid prescriptions – Winnipeg Free Press

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.